What type of study is this?

Real‐world treatment patterns among patients diagnosed with hormone receptor‐positive metastatic breast cancer in the USA

View Full Paper

Ask AI

Bookmark

There is a temporal increase in the use of aromatase inhibitors combined with CDK4/6 inhibitors for HR+ metastatic breast cancer.
Age-standardized rates showed that 48.6% of HR+/HER2− patients received first-line treatment with aromatase inhibitors.
Non-Hispanic Black and Hispanic women are less likely to receive these treatments compared to non-Hispanic White patients.
Pertuzumab treatment rates increased, but anti-HER therapy disparities remain significant among racial groups.

Authors

No takes yet. Share an insight, caveat, or question.

Analysis uncovers first-line treatment disparities for HR+ metastatic breast cancer by race and ethnicity.

Zhu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark